Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study (Feb, 10.1007/s40259-020-00409-y, 2020)-MedSci.cn - 梅斯（MedSci）

Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study (Feb, 10.1007/s40259-020-00409-y, 2020)

Ho, SL; Niu, F; Pola, S; Velayos, FS; Ning, X; Hui, RL

Hui, RL (corresponding author), Kaiser Permanente, Pharm Outcomes Res Grp, 1800 Harrison St 1301, Oakland, CA 94612 USA.

BIODRUGS, 2020; 34 (3): 405

Abstract

The article Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrat......

Full Text Link

Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

科室
- - 订阅+
  - 更多科室
工具
服务